Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) and Myelofibrosis (MF)
The goal of this clinical research study is learn if eltrombopag can help control or prevent low platelet counts in patients receiving treatment for CML or myelofibrosis.
Treatment Location: N/A
Primary: To determine the efficacy of eltrombopag for patients with chronic myeloid leukemia (CML) or myelofibrosis (MF) who have developed thrombocytopenia during the course of therapy with tyrosine kinase inhibitors (TKI) as measured by recovery of platelet count. Secondary: 1. To determine the safety of eltrombopag for patients with CML or MF who have developed thrombocytopenia during the course of therapy with TKI 2. To determine the dose intensity of TKI after start of therapy with eltrombopag 3. To determine response to TKI after start of therapy with eltrombopag
IRB Review and Approval Date: 01/13/2012
Recruitment Status: Closed
Projected Accrual: N/A